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Molecular characterization of identical, novel MLL-EPS15 translocation and individual genomic copy number alterations in monozygotic infant twins with acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) occurring in the first year of life is rare, accounting for 2-5% of pediatric ALL cases. Infant ALL is distinguished by unique clinical and biological characteristics, with an aggressive course following a short latency period. The mixed lineage leukemia (MLL) gene, located on chromosome 11q23, is involved in 80% of cases. Over 70 different MLL-fusion partner genes have been molecularly characterized, 1 with t(4;11), t(9;11) and t(11;19) occurring most frequently in infant ALL.
The outcome of MLL-rearranged infant ALL remains poor with up to 50% five-year survival.
The uncommon nature of ALL in infancy limits the rate of accrual for clinical trials and evidence for the best therapeutic approach has been conflicting, particularly regarding the benefit of hematopoietic stem cell transplantation. The clinical heterogeneity exhibited by ALL in infancy, such as poorer outcome under 90 days of age, 2 underlies the need for stratification on these trials. The age-related difference in outcome may be a reflection of underlying molecular characteristics with differences in gene expression profiles according to age. 3 Risk stratification according to MLL translocation partners has not been undertaken due to small patient numbers and as the same biological process was thought to occur irrespective of the partner gene, for MLL-mediated leukemogenesis. However, recent identification of distinct molecular differences among the MLL subtypes, including variations in epigenetic 4 and gene expression profiles, 3 has given rise to the notion that the many fusion partners of The MLL-fusion transcripts were sequenced and novel, identical breakpoints were identified in both twins, as shown in Figure 1a . For the MLL-EPS15 transcript, the breakpoint was located at the end of exon 8 of MLL, which was fused to exon 10 of EPS15. For the EPS15-MLL transcript, the breakpoint was located at the end of exon 9 of EPS15, which was fused to exon 10 of MLL. Skipping of MLL exon 9 was therefore evident at the transcriptional level. A novel, identical breakpoint was also identified at the DNA level, as shown in Figure 1b In order to detect molecular aberrations that may be unique to each twin, the Affymetrix Cytogenetics Whole-Genome 2.7M Array technology was applied. Each twin had two copynumber alterations (CNAs), shown in Table 1 , that were considered tumor-associated genomic aberrations. One CNA was common in both twins, namely amplification at Xp21.1, which is a gene poor region. This region has previously been identified with a 50kbp deletion in one infant with t(4;11) MLL-rearranged ALL. 10 The other CNAs were different for each twin, namely a 47kbp amplification at 6p12.1, which contains the GFRAL (GDNF family receptor alpha like) gene, for Twin One and a 28kbp deletion at 9q31.3, containing the MUSK (muscle, skeletal, receptor tyrosine kinase) gene, for Twin Two. Each twin had three regions of tumor-associated copy-number neutral loss of heterozygosity, shown in Table 1 , two of which were common between the twins. In addition, Twin Two had Trisomy X occurring in a subpopulation of leukemic cells, evident from both the banded chromosomal and cytogenetic array analyses.
Studies using high-resolution SNP and cytogenetic arrays in singletons with infant t(4;11)
MLL-rearranged ALL, 10,11 revealed an exceptionally low frequency of CNAs. Our results corroborate these findings in a different cytogenetic subtype of MLL-rearranged infant ALL.
Together with the concordance shown at the molecular level for the t(1;11) translocation, the identification of additional common aberrations provides further support for the concept of in utero development of a pre-leukemic clone in one twin with transfer to the other by means of the shared placental circulation. 12 The low frequency of additional aberrations points towards the t(1;11) translocation as the major driver for leukemogenesis, however, further work is required to ascertain as to whether these additional aberrations have a co-operating role.
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